Black Diamond Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 12, 2021 08:22 ET
|
Black Diamond Therapeutics, Inc
Initial Phase 1 clinical PK, safety, and preliminary efficacy data for BDTX-189 presented at ASCO Annual Meeting; on track to initiate Phase 2 portion of MasterKey-01 study in second half of...
Black Diamond Therapeutics Announces Appointment of Mark Velleca, M.D., Ph.D. to Board of Directors
August 10, 2021 07:45 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of...
Black Diamond Therapeutics to Present at Upcoming Investor Conferences
August 04, 2021 07:45 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of...
Black Diamond Therapeutics Presents Phase 1 Pharmacokinetic, Safety, and Preliminary Efficacy Data of BDTX-189 in Advanced Solid Tumors Harboring EGFR or HER2 Alterations
May 19, 2021 17:00 ET
|
Black Diamond Therapeutics, Inc
Once-daily (QD) dose escalation completed; pharmacokinetic (PK) profile consistent with design principles and preclinical predictions Generally well-tolerated with medically manageable toxicities...
Black Diamond Therapeutics to Host Webcast Presentation of Data From Phase 1 Dose-Escalation Portion of MasterKey-01 Clinical Trial
May 17, 2021 07:45 ET
|
Black Diamond Therapeutics, Inc
Company to host conference call on Wednesday, May 19, 2021 at 6:00 PM ET CAMBRIDGE, Mass. and NEW YORK, May 17, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision...
Black Diamond Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 07, 2021 07:45 ET
|
Black Diamond Therapeutics, Inc
Patient enrollment and dosing in the Phase 1/2 clinical trial of BDTX-189 continue to track in line with projections at initiation of the study, with dose-escalation portion on track to complete in...
Black Diamond Therapeutics to Present Phase 1 BDTX-189 Data in Advanced Solid Tumors at American Society of Clinical Oncology
April 28, 2021 10:38 ET
|
Black Diamond Therapeutics, Inc
Initial pharmacokinetic (PK), safety, and preliminary efficacy data from Phase 1 dose-escalation portion of MasterKey-01 clinical trial to be presented CAMBRIDGE, Mass. and NEW YORK, April 28, 2021 ...
Black Diamond Therapeutics Announces Preclinical Data Presentations on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting
April 10, 2021 08:30 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, April 10, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of...
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 25, 2021 07:45 ET
|
Black Diamond Therapeutics, Inc
Patient enrollment and dosing in the Phase 1/2 clinical trial of BDTX-189 continue to track in line with projections at initiation of the study, with dose-escalation portion on track to complete in...
Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting
March 10, 2021 16:58 ET
|
Black Diamond Therapeutics, Inc
CAMBRIDGE, Mass. and NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of...